Chemotherapy for Prostate Cancer

Gulley, James L.; Dahut, William L.

doi:10.1097/01.mjt.0000133582.68709.e3

Cited by 19 publications

(18 citation statements)

References 33 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[270][271][272][273][274][275] Employing the use of these drugs, however, has been met with only modest success due to issues of toxicity and the drug-resistant nature of CaP. Efforts to minimize drug resistance should prove effective in extending the life expectancy of HRPC patients.…”

Section: Treatment Of Prostate Cancermentioning

confidence: 99%

Targeting prostate cancer based on signal transduction and cell cycle pathways

Lee¹,

Lehmann²,

Terrian³

et al. 2008

Cell Cycle

View full text Add to dashboard Cite

Section: Treatment Of Prostate Cancermentioning

confidence: 99%

Targeting prostate cancer based on signal transduction and cell cycle pathways

Lee¹,

Lehmann²,

Terrian³

et al. 2008

Cell Cycle

View full text Add to dashboard Cite

“…Hormone-refractory or androgenindependent prostate cancer has proven to be largely resistant to conventional chemotherapy. With the exception of palliative care, the only approved chemotherapy is docetaxel in combination with prednisone, which offers a modest (2.4 months) survival benefit (4,5). New molecularly targeted therapies are urgently needed.…”

mentioning

confidence: 99%

Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen

Hopf

Malewicz

et al. 2006

Clinical Cancer Research

127

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) is the prototypic cell-surface marker of prostate cancer and provides an attractive target for monoclonal antibody (mAb) targeted therapies. In this study, a novel antibody-drug conjugate (ADC) was generated by linking a fully human PSMA mAb to monomethylauristatin E (MMAE), a potent inhibitor of tubulin polymerization. The PSMA ADC was evaluated for antitumor activity in vitro and in a mouse xenograft model of androgen-independent human prostate cancer. The PSMA ADC eliminated PSMAexpressing cells with picomolar potency and >700-fold selectivity in culture. When used to treat mice with established human C4-2 tumors, the PSMA ADC significantly improved median survival 9-fold relative to vehicle or isotype-matched ADC (P = 0.0018) without toxicity. Treatment effects were also manifest as significant (P = 0.0068) reduction in serum levels of prostate-specific antigen (PSA). Importantly, 40% of treated animals had no detectable tumor or measurable PSA at day 500 and could be considered cured. The findings support development of PSMA antibody-auristatin conjugates for therapy of prostate cancer.Prostate cancer is the most common malignancy and the second leading cause of cancer death in men in the United States (1). Localized prostate cancer typically is treated with surgery or radiation, and recurrent disease can be controlled temporarily with androgen ablation (2). However, almost all prostate carcinomas eventually become hormone refractory and then rapidly progress (3). Hormone-refractory or androgenindependent prostate cancer has proven to be largely resistant to conventional chemotherapy. With the exception of palliative care, the only approved chemotherapy is docetaxel in combination with prednisone, which offers a modest (2.4 months) survival benefit (4, 5). New molecularly targeted therapies are urgently needed.Monoclonal antibody (mAb) therapies have shown considerable use in the treatment of non-Hodgkin's lymphoma (6), B-cell chronic lymphocytic leukemia (7), colorectal carcinoma (8, 9), and breast cancer (10). In addition, mAbs have proven effective as vehicles to deliver therapeutic drugs or radionuclides in acute myeloid leukemia (11) and nonHodgkin's lymphoma (12, 13). Antibody-drug conjugates (ADC) combine the molecular targeting of mAbs with the chemotherapeutic properties of potent cytotoxins and hold great promise as molecularly targeted therapies of cancer.Prostate-specific membrane antigen (PSMA) is a very well characterized cell surface marker of prostate cancer (14 -17). PSMA is a homodimeric type II integral membrane glycoprotein whose expression is largely restricted to the prostate and is highly up-regulated in prostate carcinomas (17,18). Its expression increases with disease progression, becoming highest in metastatic, hormone-refractory disease (19). In addition, PSMA is abundantly expressed on the neovasculature of most other solid tumors but not on normal vasculature (20 -24). Importantly, PSMA is rapidly and constitutively internalized...

show abstract

“…The currently Food and Drug Administration (FDA) approved first-line chemotherapeutic agents for CRPC treatment include mitoxantrone (an anthracycline derivative [7,8], estramustine (an estrogen derivative), and docetaxel [9] Fig. (b).…”

Section: Introductionmentioning

confidence: 99%

“…Since 2004 combined administration of docetaxel (tradename Taxotere) and prednisone has been the standard first-line treatment for metastatic CRPC [9,13,14]. Additionally, docetaxel/ estramustine combinations were proposed as first-line chemotherapy against advanced prostate cancer and verified to be active, with tolerable side effects [14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

New Strategies Against Prostate Cancer – Pt(II)-Based Chemotherapy

Matos¹,

Carvalho²,

Lopes

et al. 2012

CMC

View full text Add to dashboard Cite

Prostate cancer is the second most common cancer worldwide and the sixth cause of cancer-related death in men. When hormone therapy fails to control tumour growth, castration-resistant prostate cancer (CRPC) occurs and chemotherapy drugs must be administered. Since 2004, docetaxel administration is the standard of care in metastatic CRPC, although it presents severe limitations such as acquired resistance and poor prognosis. An analogue (cabazitaxel) was approved by the FDA in 2010 as a second-line chemotherapeutic agent. Novel immuno-and hormonal therapy agents, as well as tumour vaccines, have been recently developed, but new strategies are still needed for effectively handling this type of neoplasia. Platinum compounds, in particular, have been the object of a growing interest, despite the former belief that they should have modest activity against prostate cancer. Compounds such as carboplatin, oxaliplatin or satraplatin, either alone or in combination, have lately shown promising results. In order to overcome the deleterious side-effects usually associated to these metal-based agents, several approaches have been followed with a view to optimise drug delivery and targeting, some of which showed considerable success in CRPC. Platinum drugs may therefore have an important role in the chemotherapeutic management of human metastatic castration-resistant prostate cancer, mostly in second-line strategies. The present review addresses the most relevant studies on platinum-based antineoplastic agents towards CRPC in the last decade -from first-and second-generation complexes to newly developed compounds.

show abstract

Chemotherapy for Prostate Cancer

Cited by 19 publications

References 33 publications

Targeting prostate cancer based on signal transduction and cell cycle pathways

Targeting prostate cancer based on signal transduction and cell cycle pathways

Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen

New Strategies Against Prostate Cancer – Pt(II)-Based Chemotherapy

Contact Info

Product

Resources

About